Endothelial Massive Calcium Accumulation Death (MCAD): Mechanism, Target, and Predictive Biomarker for Anti-Angiogenic Therapy by Larry  Weisenthal
Endothelial calcium accumulation death (MCAD): mechanism, target, and predictive biomarker 
for anti-angiogenic (AA) therapy. L. Weisenthal, S. Williamson, H. Liu, K. Ryan, C. Sanchez, and C. 
Reuff-Weisenthal. Weisenthal Cancer Group; Huntington Beach, CA http://medpedia.com/users/110
We cultured human umbilical vein endothelial cells with bevacizumab, tyrosine kinase inhibitors known 
to be AA, and traditional cytotoxic drugs. The images below show that, in the presence of physiological 
saline and non-favorable culture conditions, the vast majority of the endothelial cells undergo a non-
specific type of cell death (NSCD), not associated with calcium uptake, but with loss of cell membrane 
integrity, allowing uptake of the Fast Green dye, staining these dead dells a pale blue green.  In the 
presence of known AA agents (e.g. bevacizumab, some TK inhibitors) a large percentage of the 
endothelial cells undergo death associated with massive calcium accumulation (MCAD), with these cells 
staining hyperchromatic, refractile, blue-black, precisely as reported in http://www.ncbi.nlm.nih.gov/
pubmed/18793333   and  http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e13617  and 
http://tinyurl.com/weisenthal-breast-lapatinib. MCAD is strikingly demonstrated by Fast Green/Alizarin 
staining as reported in http://precedings.nature.com/documents/4499/version/1. Traditional cytotoxic 
drugs (e.g. cisplatin) produce only GVCD and inhibit MCAD.  We propose that MCAD is a cell death 
mechanism unique to endothelial cells and provides a practical biomarker to predict for AA activity in 
clinical oncology and drug development, as well as a potential drug target.
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Endothelial massive calcium-accumulation death (MCAD): mechanism, target, and predictive biomarker for anti-angiogenic therapy. 
L Weisenthal, S Williamson, H Liu, C Sanchez, K Ryan, and C Rueff-Weisenthal. Weisenthal Cancer Group, Huntington Beach, CA   http://weisenthalcancer.com
A predictive biomarker is needed for 
drug development and individualization 
of anti-angiogenic therapy
We have discovered that human endothelial 
cells undergo two forms of cell death. 
1. A non-specific form of cell death, similar to 
that of other normal and neoplastic cells 
2. A unique form of cell death, seen only in 
endothelial cells, associated with massive 
accumulation of calcium. We call this 
massive calcium accumulation death, or 
MCAD. 
3. MCAD may be identified by cytochemical 
staining with:
a. Fast Green/Hematoxylin
b. Fast Green/Wright-Giemsa, or
c. Alizarin red S (most adevantageous)
In the presence of Fast Green/
Hematoxylin, calcium is 
identified by a blue-black 
“lake” staining effect.
Human Umbilical Vein Endothelial Cells
ImageJ Color (RGB) image quantification
In general, tyrosine kinase inhibitors 
(exception: sorafenib) and mTor 
inhibitors are additive with 
bevacizumab, while traditional 
cytotoxic chemotherapy drugs inhibit 
the ability of bevacizumab to produce 
MCAD.
In the presence of Alizarin red S, 
calcium is identified by an orange-red
“lake” staining effect
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